5-hydroxybendazac has been researched along with Cataract, Membranous in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bascal, ZA; Wolff, SP; Woollard, AC | 1 |
| Harding, JJ; Lewis, BS | 1 |
2 other study(ies) available for 5-hydroxybendazac and Cataract, Membranous
| Article | Year |
|---|---|
Antioxidant characteristics of some potential anticataract agents. Studies of aspirin, paracetamol, and bendazac provide support for an oxidative component of cataract.
Topics: Acetaminophen; Ampyrone; Antioxidants; Aspirin; Biphenyl Compounds; Cataract; Chelating Agents; Erythrocytes; Free Radicals; Hemin; Humans; Hydrazines; Indazoles; Phenol; Phenols; Picrates | 1990 |
The major metabolite of bendazac inhibits the glycosylation of soluble lens proteins: a possible mechanism for a delay in cataractogenesis.
Topics: Animals; Cataract; Cattle; Crystallins; Galactose; Glucosephosphates; Glycosylation; In Vitro Techniques; Indazoles; Protein Binding; Pyrazoles | 1988 |